Efficacy and safety of neoadjuvant camrelizumab plus albumin-bound paclitaxel and carboplatin in stage II–IIIB lung squamous cell carcinoma: a single-arm, single-center, phase II trial

Background This study evaluated the preliminary efficacy and safety of neoadjuvant camrelizumab combined with albumin-bound paclitaxel and carboplatin in patients with stage II–IIIB lung squamous cell carcinoma (LUSC). Methods This prospective, single-arm, single-center phase II study enrolled 18 patients who received two to four cycles of neoadjuvant therapy, followed by surgery when feasible. Major Pathological Response (MPR) rate was the primary endpoint, and pathological response and safety were also assessed. Results All 18 patients were male, with a median age of 67 years. Fifteen patients underwent surgery, of whom 14 (93.3%) achieved R0 resection. The major pathological response (MPR) rate was 53.3% (8/15), including a pathological complete response (pCR) rate of 33.3% (5/15). Conversion from video-assisted thoracoscopic surgery to open thoracotomy was required in eight patients (53.3%), primarily because of severe pleural adhesions. No 30- or 90-day postoperative deaths or grade 5 adverse events occurred. After a median follow-up of 28.5 months, one recurrence was observed among the 15 surgical patients, whereas all three patients who did not undergo surgery had died. The estimated 1- and 2-year overall survival rates were 94.4% and 88.1%, respectively; the estimated 1- and 2-year DFS rates were both 100%. Conclusions Neoadjuvant camrelizumab combined with albumin-bound paclitaxel and carboplatin showed preliminary antitumor activity in patients with stage II–IIIB LUSC. However, the small sample size, single-arm design, and limited follow-up preclude definitive conclusions regarding efficacy and long-term benefit. Larger prospective controlled studies with longer follow-up are warranted. Trial registration: Chinese Clinical Trial Registry (ChiCTR); identifier: ChiCTR2200060165. Public website: https://www.chictr.org.cn/ .

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-12
DOI
https://doi.org/10.3389/fonc.2026.1998532
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and safety of neoadjuvant camrelizumab plus albumin-bound paclitaxel and carboplatin in stage II–IIIB lung squamous cell carcinoma: a single-arm, single-center, phase II trial

Sha Liu, Haoran Xu, Yuhong Ma, Changchun Shao et al.
Frontiers in Oncology
Lung Cancer Diagnosis and Treatment
article

Efficacy and safety of neoadjuvant camrelizumab plus albumin-bound paclitaxel and carboplatin in stage II–IIIB lung squamous cell carcinoma: a single-arm, single-center, phase II trial

Sha Liu, Haoran Xu, Yuhong Ma, Changchun Shao, Ningning Kang, Yao Fu, Shangjia Gui, Yiruo Zhang, Junjun Lu, Yuanyuan Shen, Yingying Du, Xilang Wang, Hua Wang, Ziming Li
article en

Abstract

Background This study evaluated the preliminary efficacy and safety of neoadjuvant camrelizumab combined with albumin-bound paclitaxel and carboplatin in patients with stage II–IIIB lung squamous cell carcinoma (LUSC). Methods This prospective, single-arm, single-center phase II study enrolled 18 patients who received two to four cycles of neoadjuvant therapy, followed by surgery when feasible. Major Pathological Response (MPR) rate was the primary endpoint, and pathological response and safety were also assessed. Results All 18 patients were male, with a median age of 67 years. Fifteen patients underwent surgery, of whom 14 (93.3%) achieved R0 resection. The major pathological response (MPR) rate was 53.3% (8/15), including a pathological complete response (pCR) rate of 33.3% (5/15). Conversion from video-assisted thoracoscopic surgery to open thoracotomy was required in eight patients (53.3%), primarily because of severe pleural adhesions. No 30- or 90-day postoperative deaths or grade 5 adverse events occurred. After a median follow-up of 28.5 months, one recurrence was observed among the 15 surgical patients, whereas all three patients who did not undergo surgery had died. The estimated 1- and 2-year overall survival rates were 94.4% and 88.1%, respectively; the estimated 1- and 2-year DFS rates were both 100%. Conclusions Neoadjuvant camrelizumab combined with albumin-bound paclitaxel and carboplatin showed preliminary antitumor activity in patients with stage II–IIIB LUSC. However, the small sample size, single-arm design, and limited follow-up preclude definitive conclusions regarding efficacy and long-term benefit. Larger prospective controlled studies with longer follow-up are warranted. Trial registration: Chinese Clinical Trial Registry (ChiCTR); identifier: ChiCTR2200060165. Public website: https://www.chictr.org.cn/ .

Frontiers in OncologyVol. 16
Shanghai Jiao Tong University (CN), Anhui Medical University (CN), Shanghai Chest Hospital (CN), First Affiliated Hospital of Anhui Medical University (CN)
Good health and well-being
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon